Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | EDNRB | P24530 | 2/20 | 0.36 |
| ▸ | EDNRA | P25101 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568566 | 0.81 | KEAP1 (0.47) | KEAP1ALDH1A1MEN1KMT2APKM | |
| Ammonia Solution, Strong SCHEMBL2980807 | 0.79 | KEAP1 (0.46) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL14401693 | 0.79 | ALDH1A1 (0.48) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4973829 | 0.77 | KEAP1 (0.42) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL23569845 | 0.76 | KEAP1 (0.43) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL1760843 | 0.76 | TRPV4 (0.42) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL13592488 | 0.76 | KEAP1 (0.46) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL12261098 | 0.73 | MAPT (0.44) | KEAP1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL2981246 | 0.72 | ACHE (0.33) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL12086771 | 0.70 | MAPT (0.49) | ALDH1A1MEN1KMT2AEDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1745032-B1 | CXCR1 and CXCR2 chemokine antagonists | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-7671212-B2 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-1694659-B8 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-7338968-B2 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1697354-A1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1694659-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060014794-A1 | CXCR1 and CXCR2 chemokine antagonists | SCHERING CORPORATION | 2006-01-19 | — | — | US | disclosed |
| WO-2005113534-A2 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005068460-A1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005066147-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1551818-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | Pharmacopeia Drug Discovery, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION PHARMACOPEIA, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | KEAP1 781/4885ALDH1A1 500/4885MEN1 4674/4885 |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | CCR2, CXCR1, CXCR2 | KEAP1 518/4885ALDH1A1 944/4885MEN1 4757/4885 |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | KEAP1 296/4885ALDH1A1 254/4885MEN1 4704/4885 |
| US-20060014794-A1 | CXCR1 and CXCR2 chemokine antagonists | CXCR1, CXCR2, CXCR5 | KEAP1 1332/4885ALDH1A1 1045/4885MEN1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.